Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • As stipulated in the Decree on Drugs (Price Control) 2013, the NPPA sets the ceiling price for essential drugs in Schedule I. According to the National Pharmaceutical Pricing Authority (NPPA), "few" drugs will be taken care of as part of patient relief measures.

  • Allowing insurers to market healthcare policies across state lines is one of President Donald Trump's main ideas to cut costs. While supporters of the idea cast it as a way to make insurance policies more competitive, critics say it's unlikely to result in more affordable plans and could undermine stronger consumer protections in states such as California and Hawaii. Such a "race to the bottom" could leave some older consumers with health problems unable to afford coverage.

  • ICRA expects annual revenue growth of 12-14 percent over the next five years in the health care sector, in line with the trend over the last three years. The health care sector is expected to grow by 12 to 14 percent annually over the next five years, due to increased medical tourism and penetration of health insurance, rating agency ICRA said.

  • In a letter to Prime Minister Narendra Modi, the Alliance of Doctors for Ethical  Healthcare (ADEH) said that these drugs and implants are also accused of "exorbitantly" like coronary stents. ADEH has also attached documents to show how drug providers, especially those for cancer, and knee and hip replacement implants are exorbitant prices, sometimes 200 percent more than the actual price.

  • The explosive growth of the Indian pharmaceutical industry over the last decade has made the nation the host of most FDA-approved plants outside the United States.
    Leaders of two of India's largest drug manufacturers said the integration of electronic systems to avoid quality failures in factories is proceeding more slowly than expected, as industry intends to adapt to Enhanced regulatory oversight in developed countries.

  • A health ministry subject expert committee (SEC) approved Gujarat-based Meril Life Science’s bioresorbable vascular scaffold (BVS) at a meeting, a senior government official told ET on condition of anonymity. The official approval of the government to market the stent is expected in a few weeks, said the official.The health ministry has approved the country’s first locally made bioresorbable cardiac scaffold, or naturally dissolving stent for clearing blockages in arteries that carry blood to the heart.

  • The Ministry of Health circulated a Cabinet memorandum on the 2016 National Medical Commission bill proposing to reorganize the Medical Council of India (MCI). The bill, based on the recommendations of the committee of experts Niti Aayog appointed by Prime Minister Narendra Modi last year, proposes to create the commission in place of MCI.

Subscribe to Pharma News